JAMA
JAMA company profile
Latest price
As of — · Market data by Massive
Market cap
—
Volume
—
Previous close
—
Day range
—
Listed
—
Coverage
5 articles
Price performance
Recent trading
Newsroom
Latest JAMA coverage
Study finds equitable heart failure care, but challenges remain
[ad_1] (NewMediaWire) – April 19, 2023 – DALLAS — Black adults with heart failure (HF) are more likely to die than white adults with the same condition.[1] A new study published today in JAMA Cardiology that used the American Heart Association’s Get With The Guidelines® – Heart Failure registry data to examine quality and outcomes ...
Daily e-cigarette use rising despite slight decline in current use among youngest adults
[ad_1] (NewMediaWire) – July 22, 2022 – DALLAS — While overall current electronic cigarette use (meaning use within the past 30 days) fell slightly in 2020 from previous years, daily e-cigarette use has been steadily increasing among U.S. adults, according to new research supported by the American Heart Association’s Tobacco Center of Regulatory
Social impact entrepreneurs: Funding available for food access solutions in Chicago and Atlanta
[ad_1] DALLAS, November 24, 2020 — Businesses and nonprofits that are working to sustainably address food insecurity in Chicago and Atlanta may be eligible for more than $4.5 million in social impact funding through the American Heart Association’s Bernard J. Tyson Impact Fund. The national fund invests in evidence-based, community-driven entrepreneurial sol
These Eye Problems Could Be Symptoms Of COVID-19 Coronavirus
Looks like the eyes may have it. You know those round things that sit below your forehead and you use to “wink and gun” at people? Well, add them to the growing list of body parts that may be affected by the COVID-19 coronavirus. A study recently published in JAMA Ophthalmology found that 31.6% of 38 consecutive patients with COVID-19 ...
Disclosure, finances, and the oncologist
[ad_1] Conflict-of-interest guidelines missing enforcement According to the BMJ, oncologists in the US have an issue with disclosure. Research in the journal JAMA Oncology has revealed a major variety of US oncologists are failing to reveal funds from trial sponsors. Researchers now know that quite a few FDA-approved medicines that efficiently handed trials